ARCA Biopharma Surge to 52-Week High on Oruka Reverse Merger Deal

Dow Jones

Apr 03, 2024

By Colin Kellaher

ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka Therapeutics.

Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session.

ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases.

The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2024 10:35 ET (14:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2424842371"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2424842371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2424842371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424842371","market":"us","top_or_hot":-1,"title":"ARCA Biopharma Surge to 52-Week High on Oruka Reverse Merger Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session. \n</p>\n<p>\n  ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases. \n</p>\n<p>\n  The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2024 10:35 ET (14:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARCA Biopharma Surge to 52-Week High on Oruka Reverse Merger Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARCA Biopharma Surge to 52-Week High on Oruka Reverse Merger Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-04-03 22:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session. \n</p>\n<p>\n  ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases. \n</p>\n<p>\n  The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2024 10:35 ET (14:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2424842371","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424842371","pubTimestamp":1712154900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka Therapeutics.Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session.ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases.The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"ARCA Biopharma因Oruka反向合并交易飙升至52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABIO":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka Therapeutics. \n\n\n  Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session. \n\n\n  ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases. \n\n\n  The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2024 10:35 ET (14:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}